Martin Babler

Martin Babler

President, Chief Executive Officer, and Chairman of the BoardatAlumis· In proxies 2023–2025

Pay in FY2025-44% from the year before · Alumis stock +24.2% the same year

Martin Babler was paid $5.9M in FY2025 (Dec), down 44%. Alumis stock rose 24.2% that year.

Pay$100 in the stock at the end of FY24 → $124
Pay is from the Summary Compensation Table of each Alumis proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. AlumisPublic company · 3 yr
    • President, Chief Executive Officer, and Chairman of the Board2023 – Present · 3 yrStock in role -46%
  2. Prelude Therapeutics Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. 89bio Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Neoleukin Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Omega Alpha SPACPublic company
    • Director? – PresentNo stock prices for these years
  6. Sardona Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?